Compare FIGS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIGS | HROW |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2021 | 2008 |
| Metric | FIGS | HROW |
|---|---|---|
| Price | $13.43 | $33.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $15.93 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 2.3M | 487.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 850.00 | 71.43 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $419,591,000.00 | N/A |
| Revenue This Year | $14.09 | $31.62 |
| Revenue Next Year | $7.72 | $50.77 |
| P/E Ratio | $69.39 | ★ N/A |
| Revenue Growth | ★ 59.47 | N/A |
| 52 Week Low | $6.58 | $28.54 |
| 52 Week High | $17.48 | $54.98 |
| Indicator | FIGS | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 49.27 | 35.19 |
| Support Level | $12.88 | $32.46 |
| Resistance Level | $15.94 | $36.37 |
| Average True Range (ATR) | 0.67 | 1.33 |
| MACD | -0.17 | -0.10 |
| Stochastic Oscillator | 59.07 | 20.66 |
FIGS Inc is a healthcare apparel company. It designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear, and other healthcare apparel. The company sells products mainly through its direct-to-consumer (DTC) digital platform, consisting of its website, mobile app, and B2B business (TEAMS). It also operates physical retail stores, which are called Community Hubs, providing a retail experience for healthcare professionals. The company generates maximum revenue from the sale of scrubwear products. Geographically, it derives maximum revenue from the United States, followed by the rest of the world.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.